Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
For clinically important hypotension resulting primarily from vasodilation. Sold as Phenylephrine Hydrochloride, Immphentiv, Vazculep, Biorphen, Phenylephrine Hydrochloride In 0.9% Sodium Chloride. Every FDA application for this active ingredient: 6 branded and 27 generic.
As of Nov 15, 2026, FDA lists 33 applications for Phenylephrine Hydrochloride (sold as Phenylephrine Hydrochloride, Immphentiv, Vazculep and others), first approved Dec 20, 2012, with 1 new use approved and 0 published complete response letters.
First approved: Dec 20, 2012
Applications: 33
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $25K
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Phenylephrine HCl
Part D
$16K
-66%
458
IMMPHENTIV
Part B
$9K
New
1,766
Biorphen
Part B
$0K
-100%
0
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
PHENYLEPHRINE 10% EYE DROP: $5.27 per MLGeneric · new this year
PHENYLEPHRINE 2.5% EYE DROP: $9.08 per MLGeneric · -20% in a year
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Hikma
Alcon
Fresenius Kabi USA
Sandoz
Accord Hlthcare
Eugia Pharma
Baxter Hlthcare Corp
Nephron